Crinetics Pharmaceuticals, Inc. (CRNX) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $38.93 (+0.39%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 12, 2026 | Richard Law | Goldman Sachs | $67.00 | +72.1% |
| Jan 5, 2026 | Alex Thompson | Stifel Nicolaus | $75.00 | +92.7% |
| Sep 26, 2025 | Jonathan Wolleben | JMP Securities | $143.00 | +267.3% |
| Jul 10, 2025 | Richard Law | Goldman Sachs | $36.00 | -7.5% |
| Mar 24, 2025 | Alex Thompson | Stifel Nicolaus | $60.00 | +54.1% |
| Aug 9, 2024 | Douglas Tsao | H.C. Wainwright | $69.00 | +77.2% |
| Jun 4, 2024 | Leland Gershell | Oppenheimer | $74.00 | +90.1% |
| May 23, 2024 | Brian Skorney | Robert W. Baird | $62.00 | +59.3% |
| May 22, 2024 | Jeffrey Hung | Morgan Stanley | $70.00 | +79.8% |
| May 7, 2024 | Yasmeen Rahimi | Piper Sandler | $97.00 | +149.2% |
| Mar 20, 2024 | Jonathan Wolleben | JMP Securities | $80.00 | +105.5% |
| Mar 13, 2024 | Leland Gershell | Oppenheimer | $54.00 | +38.7% |
| Aug 31, 2023 | Leland Gershell | Oppenheimer | $40.00 | +2.7% |
Top Analysts Covering CRNX
CRNX vs Sector & Market
| Metric | CRNX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.41 |
| Analyst Count | 6 | 8 | 18 |
| Target Upside | +122.5% | +1150.1% | +14.9% |
| P/E Ratio | -7.71 | 6.88 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $10M | $12M | $14M | 8 |
| 2026-09-30 | $12M | $17M | $21M | 4 |
| 2026-12-31 | $17M | $24M | $29M | 7 |
| 2027-03-31 | $23M | $31M | $38M | 4 |
| 2027-06-30 | $31M | $42M | $51M | 6 |
| 2027-09-30 | $37M | $50M | $62M | 4 |
| 2027-12-31 | $47M | $63M | $78M | 7 |
| 2028-12-31 | $418M | $418M | $418M | 7 |
| 2029-12-31 | $717M | $933M | $1.14B | 3 |
| 2030-12-31 | $1.23B | $1.59B | $1.94B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-1.53 | $-1.21 | $-0.70 | 8 |
| 2026-09-30 | $-1.60 | $-1.22 | $-0.80 | 3 |
| 2026-12-31 | $-1.58 | $-1.21 | $-0.80 | 6 |
| 2027-03-31 | $-1.43 | $-1.10 | $-0.72 | 3 |
| 2027-06-30 | $-1.34 | $-1.03 | $-0.68 | 5 |
| 2027-09-30 | $-1.29 | $-0.99 | $-0.65 | 3 |
| 2027-12-31 | $-1.19 | $-0.91 | $-0.60 | 6 |
| 2028-12-31 | $-3.72 | $-2.47 | $-0.99 | 5 |
| 2029-12-31 | $0.67 | $0.95 | $1.22 | 1 |
| 2030-12-31 | $3.45 | $4.93 | $6.33 | 1 |
Frequently Asked Questions
What is the analyst consensus for CRNX?
The consensus among 6 analysts covering Crinetics Pharmaceuticals, Inc. (CRNX) is Buy with an average price target of $86.60.
What is the highest price target for CRNX?
The highest price target for CRNX is $143.00, set by Jonathan Wolleben at JMP Securities on 2025-09-26.
What is the lowest price target for CRNX?
The lowest price target for CRNX is $36.00, set by Richard Law at Goldman Sachs on 2025-07-10.
How many analysts cover CRNX?
6 analysts have issued ratings for Crinetics Pharmaceuticals, Inc. in the past 12 months.
Is CRNX a buy or sell right now?
Based on 6 analyst ratings, CRNX has a consensus rating of Buy (2.00/5) with a +122.5% upside to the consensus target of $86.60.
What are the earnings estimates for CRNX?
Analysts estimate CRNX will report EPS of $-1.21 for the period ending 2026-06-30, with revenue estimated at $12M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.